Amgen Inc.
Amgen Inc.
Your view on AMGN
Overview
What the company does, where it operates, and who runs it.
About Amgen Inc.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Robert A. Bradway
- Headquarters
- One Amgen Center Drive, Thousand Oaks, CA, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Robert A. Bradway
- Headquarters
- One Amgen Center Drive, Thousand Oaks, CA, US
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.
The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.
It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer.
It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Amgen Inc. from FRC's valuation model, read against the market price. AMGN last traded at $462.32, 26.6× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Amgen Inc.. Starting points for Amgen Inc.: P/E 26.6, EPS $17.36, beta 0.42 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Amgen Inc.. Amgen Inc. paid $9.94 per share over the last year — a 2.2% yield at the current $462.32 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Amgen Inc.. Trailing twelve-month EPS for Amgen Inc. stands at $17.36. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$423.13
average of 23 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy8
- Hold15
- Sell2
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $5.63 | $5.71 | $23.55 | $25.07 |
| Low estimate | $5.21 | $5.40 | $23.20 | $23.54 |
| High estimate | $6.12 | $6.04 | $24.15 | $26.59 |
| No. of analysts | 18 | 6 | 19 | 20 |
| Year-ago EPS | $5.29 | $5.15 | $14.23 | — |
| Growth | +6.4% | +10.9% | +65.5% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $10.45B | $9.56B | $39.46B | $41.29B |
| Low estimate | $10.33B | $9.22B | $39.03B | $40.37B |
| High estimate | $10.54B | $10.26B | $39.89B | $42.42B |
| No. of analysts | 15 | 5 | 23 | 24 |
| Year-ago revenue | $9.87B | $8.62B | $36.74B | — |
| Growth | +6.0% | +10.9% | +7.4% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, MarketWatch; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Amgen Inc.. Amgen Inc. has reported as a listed company since 1983. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ABBVAbbVie Inc.Drug Manufacturers - General$520.9B
- AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
- BMYBristol-Myers Squibb CompanyDrug Manufacturers - General$128.6B
- GSKGSK plcDrug Manufacturers - General$97.5B
- JNJJohnson & JohnsonDrug Manufacturers - General$687.9B
- LLYEli Lilly and CompanyDrug Manufacturers - General$1.3T
- MRKMerck & Co., Inc.Drug Manufacturers - General$356.1B
- NVSNovartis AGDrug Manufacturers - General$302.6B
More Drug Manufacturers - General companies
- OPHLFOno Pharmaceutical Co., Ltd.OTC$7.8B
- OPHLYOno Pharmaceutical Co., Ltd.OTC$7.9B
- ORINFOrion OyjOTC$11.1B
- ORINYOrion OyjOTC$22.8B
- OTSKFOtsuka Holdings Co., Ltd.OTC$35.4B
- OTSKYOtsuka Holdings Co., Ltd.OTC$36.6B
- PFEPfizer Inc.NYSE$159.9B
- PFE.NEPfizer Inc.NEO
- PTKFFPT Kalbe Farma Tbk.OTC$3.2B
- PTKFYPT Kalbe Farma Tbk.OTC$15M
- RHHBFRoche Holding AGOTC$390.8B
- RHHBYRoche Holding AGOTC$383.1B
ETFs holding Amgen Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.39%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.35%
- QQQInvesco QQQ Trust, Series 1$446.1B in assets1.17%
- SCHDSchwab U.S. Dividend Equity ETF$119.9B in assets4.08%
- BBHVanEck Biotech ETF$536M in assets16.87%
- IBBiShares Biotechnology ETF$11.1B in assets8.58%
- DIVOAmplify CWP Enhanced Dividend Income ETF$7.9B in assets5.77%
- HHL.TOHarvest Healthcare Leaders Income ETF$2.2B in assets4.80%
Largest holders first, then the funds most concentrated in AMGN.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Amgen Inc., and how their positions are changing. At a $250.07B market value, institutional positions materially move Amgen Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Amgen Inc. executives and directors. Shares of Amgen Inc. have traded between $253.30 and $345.84 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Amgen Inc.. Amgen Inc. is a $250.07B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Amgen Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Amgen Inc.. Coverage tracks Amgen Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Amgen Inc.